Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study to Evaluate the Efficacy and Safety of Telisotuzumab Adizutecan in Combination With RC148 as First-Line Therapy for Non-Squamous Non-Small-Cell Lung Cancer

NCT07874282 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.

NCT NCT07874282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07874282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study to Evaluate the Efficacy and Safety of Telisotuzumab Adizutecan in Combination With RC148 as First-Line Therapy for Non-Squamous Non-Small-Cell Lung Cancer
Lead sponsor
RemeGen Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
February 28, 2029
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with locally advanced or metastatic non-squamous nsclc requiring first-line treatment and no driver gene alterations confirmed by histology or cytology